Multifocal intraocular lenses (IOLs) are the most exciting advance in
cataract and presbyopia corrective surgery in 25 years; meeting the
expectations of a growing population striving for an active life with
minimal or no support from eye glasses.
TORONTO, Feb. 17 /CNW/ - The mission over the years has been to provide a
surgical application for multifocal vision correction. Patients wanted to
improve their quality of life and surgeons wanted a product with a
predictability of vision results and high patient satisfaction.
Dr. Christoph Kranemann, a leader in ophthalmology, laser eye surgery and
complex cataract and glaucoma surgery, was the first surgeon in Canada to
provide a new remarkable surgical solution. "I chose the Acri.LISA(R) lens
because by design it is least likely to give patients any undesirable side
effects. Comparatively it has been a challenge to give people a quick and good
intermediate vision by using the same lens in both eyes."
Dr. Kranemann's first patient was Hannelore, a 63 year old woman. She had
worn glasses since adolescence, but since her early 50's was having a rapid
decline in her vision.
Hannelore explained, "I was constantly needing new eye glasses because my
eyesight was changing every few months, and to make matters worse, each eye
needed a different correction. It was not unusual for me to carry several
pairs of glasses for different tasks such as reading - which was often fuzzy,
walking, using the computer and driving. Night-time driving was not possible
and I was restricted in my normal activities, always trying to maintain my
ability to see."
Hannelore's condition is not that uncommon and the Acri.LISA(R) lens was
designed to allow patients to see close-up, distant and in-between without
relying on a collection of eye glasses.
Hannelore recalled, "I had my first eye operated on Oct.2nd, 2008. I was
very anxious, yet very hopeful. To my amazement I could see more clearly
immediately, right after the surgery and by the following day I could see
things I never could before."
Dr. Kranemann, pleased with the results, observed that there were "No
negative symptoms post-op". He performed the second surgery the same month on
Oct. 30th 2008. He detailed, "There are limitations with other technologies,
including halos and glares - particularly in the first six months, compounding
a challenge for a mix and match system lens to address near, distance and
Hannelore was thrilled. "It was a miracle and even though both of my eyes
had different vision issues, now I don't need to wear any glasses at all. I
can even see to pluck my eyebrows. My life has totally changed. I feel
independent. I can even drive at night."
Dr. Kranemann stated, "the most significant difference post-op was true
ecstatic patient responses and they have reported absolutely no negative
symptoms whatsoever. I look forward to using this product more frequently and
I feel that the Acri.LISA(R) lens is certainly very promising."
Dr. Kranemann will continue to obtain long-term data to collaborate his
initial results and plans to present his findings on the Acri.LISA(R) lens to
his peers at various upcoming meetings of the Ophthalmology Societies.
Acri.LISA(R) - Improving the Quality of Life
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of
the German stock exchange, is one of the world's leading medical technology
The Company supplies innovative technologies and application-oriented
solutions which enable doctors to improve the quality of life of their
patients. The Company offers complete solutions, including implants and
consumables, to diagnose and treat ophthalmic diseases. In the field of
Neuro/ENT surgery the Company provides innovative visualization solutions.
Carl Zeiss Meditec's medical technology portfolio is rounded off by promising
future technologies such as intraoperative radiotherapy.
The Company's around 2,100 employees generated revenue of about EUR 600
million in fiscal year 2007/08 (ended Sept. 30). The headquarters of Carl
Zeiss Meditec are located in Jena, Germany. In addition to other subsidiaries
in Germany, the Company is represented by over 50 percent of its employees at
sites in the USA, Japan, Spain and France.
Thirty-five percent of Carl Zeiss Meditec's shares are in free float. The
remaining 65 percent are held by Carl Zeiss AG, one of the world's leading
groups engaged in the optical and opto-electronics industry. The five
independently run business segments of Carl Zeiss AG operate in the
future-oriented markets "Medical and Research Solutions", "Industrial
Solutions" and "Lifestyle Products". Carl Zeiss AG is headquartered in
Oberkochen, Germany. During fiscal year 2007/08 (ended Sept. 30) the company
generated revenues of about EUR 2.7 billion. Carl Zeiss has around 13,000
employees in more than 30 countries, including more than 8,000 in Germany.
For further information please visit our website at:
For further information:
For further information: MEDIA CONTACT: For more information or to
arrange an interview with Dr. Kranemann please contact: Sandra Freer, SDA
Communications at (416) 239-0781, firstname.lastname@example.org; Acri.LISA(R) Lens -
Carl Zeiss Canada Ltd., Toronto, Ontario, email@example.com, www.zeiss.ca